Blueprint Medicines is revising a pact with VantAI again, this time adding a focus for historically “undruggable” targets and ...

A dementia-focused transatlantic venture capital initiative has secured $269 million in commitments for its second fund. | A ...

Pacibekitug, an antibody targeting interleukin-6, hit the primary endpoint in the phase 2 Tranquility trial by sharply ...

Fierce 15 nominations are open! We're searching for the most innovative, resourceful and visionary biotechs leading the way ...

RegenXBio will fill its coffers with up to $250 million by monetizing more royalty rights for Novartis-partnered Zolgensma, ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the ...

Despite hitting a clinical “milestone,” Prime Medicine is shelving its sole clinical-stage genetic medicine. | Despite ...

Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease ...

Recent lawsuits from nonprofits, state attorneys general, unions and local governments say the reorganizations and reductions ...

The company has signed up to pay $256 million for 23andMe and nearly all of its assets, including its R&D services operations ...

Pfizer-backed CellCentric has secured $120 million in series C funds as the British biotech prepares to take its multiple ...